新辅助奥希替尼治疗可切除EGFR突变非小细胞肺癌
这项随机对照III期研究纳入358例可切除、EGFR突变、II-IIIB期非小细胞肺癌患者,按1:1:1随机接受新辅助奥希替尼联合铂类化疗、奥希替尼单药或安慰剂联合铂类化疗。主要终点主要病理缓解率分别为26%、25%和2%,联合化疗与单药均较安慰剂联合化疗显著改善;12个月无事件生存率分别为93%、95%和83%,数据成熟度15%。
要点
- 新辅助奥希替尼联合化疗主要病理缓解率26%,奥希替尼单药25%,均显著高于安慰剂联合化疗的2%。
- 12个月无事件生存率:联合化疗93%、单药95%、安慰剂联合化疗83%,数据成熟度15%。
- 新辅助期≥3级任何原因不良事件发生率分别为36%、13%和33%,未发现新的安全性问题。
核心结论
- 在可切除、EGFR突变、II-IIIB期非小细胞肺癌患者中,新辅助奥希替尼联合或不联合化疗较单纯化疗显著改善主要病理缓解率。
研究设计与样本
- 随机对照III期研究,358例可切除、EGFR突变、II-IIIB期非小细胞肺癌患者按1:1:1随机分组。
- 奥希替尼联合化疗组121例,奥希替尼单药组117例,安慰剂联合化疗组120例。
- 新辅助奥希替尼80 mg口服每日一次持续≥9周,联合铂类化疗每3周一次共三周期;奥希替尼单药持续≥9周;对照组为安慰剂联合铂类化疗,随后行手术切除。
- 主要终点为主要病理缓解率,由盲法中心病理审查评定;无事件生存率为次要终点。
主要发现
- 主要病理缓解率:奥希替尼联合化疗组26%,奥希替尼单药组25%,安慰剂联合化疗组2%。
- 奥希替尼联合化疗对比安慰剂联合化疗的比值比为19.82(95.002% CI,4.60至85.33;P < .0001)。
- 奥希替尼单药对比安慰剂联合化疗的比值比为19.28(99.9% CI,1.71至217.39;P < .0001)。
- 数据成熟度15%时,12个月无事件生存率分别为奥希替尼联合化疗组93%、奥希替尼单药组95%、安慰剂联合化疗组83%。
- 新辅助期≥3级任何原因不良事件发生率分别为奥希替尼联合化疗组36%、奥希替尼单药组13%、安慰剂联合化疗组33%;未发现新的安全性问题。
关键数值与推荐
- 主要病理缓解率:奥希替尼联合化疗组26% vs 安慰剂联合化疗组2%,比值比19.82(95.002% CI,4.60至85.33;P < .0001)。
- 主要病理缓解率:奥希替尼单药组25% vs 安慰剂联合化疗组2%,比值比19.28(99.9% CI,1.71至217.39;P < .0001)。
- 12个月无事件生存率:奥希替尼联合化疗组93%、奥希替尼单药组95%、安慰剂联合化疗组83%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adjuvant osimertinib is the standard of care for patients with resected epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term outcomes. METHODS: In this randomized, controlled, phase III study, patients with resectable, EGFR-mutated, stage II-IIIB NSCLC were randomly assigned (1:1:1) to receive neoadjuvant osimertinib (80 mg orally once daily for ≥9 weeks) plus platinum-based chemotherapy (once every 3 weeks for three cycles), osimertinib monotherapy (for ≥9 weeks), or placebo plus platinum-based chemotherapy (control), followed by surgical resection. Adjuvant osimertinib was offered to eligible patients after completion of surgery. The primary end point was major pathologic response (MPR) by blinded central pathology review. Event-free survival (EFS) was a secondary end point. RESULTS: Overall, 358 patients were randomly assigned to receive osimertinib plus chemotherapy (121 patients), osimertinib monotherapy (117 patients), or placebo plus chemotherapy (120 patients). Osimertinib plus chemotherapy (MPR rate 26%) and osimertinib monotherapy (25%) demonstrated statistically significant improvement in the MPR rate versus placebo plus chemotherapy (2%), with corresponding odds ratios of 19.82 (95.002% CI, 4.60 to 85.33; P < .0001) and 19.28 (99.9% CI, 1.71 to 217.39; P < .0001), respectively. With 15% data maturity, the EFS rates at 12 months were 93%, 95%, and 83% with osimertinib plus chemotherapy, osimertinib monotherapy, and placebo plus chemotherapy, respectively. In the neoadjuvant period, grade ≥3 adverse events of any cause occurred in 36%, 13%, and 33% of patients with osimertinib plus chemotherapy, osimertinib monotherapy, and placebo plus chemotherapy, respectively. No new safety concerns were identified. CONCLUSION: Neoadjuvant osimertinib with or without chemotherapy demonstrated statistically significant improvement in the MPR rate over chemotherapy alone in patients with resectable, EGFR-mutated, stage II-IIIB NSCLC.
引用
- He J, Tsuboi M, Weder W, et al. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. J Clin Oncol. 2025. PMID: 40454705. doi:10.1200/JCO-25-00883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。